USPTO serial 87425805
L
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- KEELEY, ALISON REBECCA
- Law office
- TTAB
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with L?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Timothy T. Wang
TIMOTHY T WANG NI WANG & MASSAND PLLC8140 WALNUT HILL LANESUITE 500DALLAS, TX 75231Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations, for treating diseases of cardiovascular system, for treating diseases of cerebrovascular system, for use in haematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system, immune system and musculo-skeletal system, and for treating hypersensitivity diseases; Medicines for human purpose, for treating diseases of cardiovascular system, for treating diseases of cerebrovascular system, for use in haematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system, immune system and musculo-skeletal system, and for treating hypersensitivity diseases; Biological preparations for medical purposes, namely, for treating diseases of cardiovascular system, for treating diseases of cerebrovascular system, for use in haematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system, immune system and musculo-skeletal system, and for treating hypersensitivity diseases; Biochemical medicines, for treating diseases of cardiovascular system, for treating diseases of cerebrovascular system, for use in haematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system, immune system and musculo-skeletal system, and for treating hypersensitivity diseases; Drugs for medical purposes in the nature of medicines, for the prevention and treatment of disorders of the nervous system, the immune system, the cardiovascular system, the cerebrovascular system, the metabolic system, the respiratory system, the musculo-skeletal system, digestive system, endocrine system, for the treatment of infective diseases, for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Injections, namely, vaccines and injectable medicines, for the prevention and treatment of disorders of the nervous system, the immune system, the cardiovascular system, the cerebrovascular system, the metabolic system, the respiratory system, the musculo-skeletal system, digestive system, endocrine system, for the treatment of infective diseases, for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Active pharmaceutical ingredients in the nature of components of finished pharmaceutical preparations, which are used for the prevention and treatment of disorders of the nervous system, the immune system, the cardiovascular system, the cerebrovascular system, the metabolic system, the respiratory system, the musculo-skeletal system, digestive system, endocrine system, for the treatment of infective diseases, for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Dietetic substances adapted for medical use, namely, dietetic beverages and food for medical purposes, the foregoing dietetic food and beverages containing vitamin, protein, minerals, lecithin, glucose, amino acid, folic acid, fruit juice, fruit oil, honey, seaweed glue, fish oil, cod-liver oil, cubilose, restoratives, plant fibre, nutrition powder, nutrient capsule, nutrient tablets, and containing mineral food-supplements, the foregoing dietetic foods and beverages are used for treating diseases of cardiovascular system, for treating diseases of cerebrovascular system, for use in haematology, dermatology, ophthalmology and gastroenterology, anti-infectives, antitumor drugs, for treating metabolic diseases, for treating nervous system diseases, for treating diseases of respiratory system, digestive system, endocrine system, immune system and musculo-skeletal system, and for treating hypersensitivity diseases | ABANDONED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jan 29, 2018 | MAB4 | ABANDONMENT NOTICE MAILED - INTER PARTES DECISION | — |
| Jan 27, 2018 | ABN4 | ABANDONMENT - AFTER INTER PARTES DECISION | — |
| Jan 27, 2018 | OP.T | OPPOSITION TERMINATED NO. 999999 | — |
| Jan 27, 2018 | OP.S | OPPOSITION SUSTAINED NO. 999999 | — |
| Oct 19, 2017 | OP.I | OPPOSITION INSTITUTED NO. 999999 | — |
| Oct 19, 2017 | OPPF | OPPOSITION PAPERS RECEIVED AT TTAB | — |
| Sep 19, 2017 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 19, 2017 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 30, 2017 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jul 27, 2017 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 27, 2017 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jul 27, 2017 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jul 27, 2017 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jul 27, 2017 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jul 24, 2017 | DOCK | ASSIGNED TO EXAMINER | — |
| May 4, 2017 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| May 3, 2017 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 29, 2017 | NWAP | NEW APPLICATION ENTERED | — |